Excisional lymph node biopsy should be preferred for the diagnostics of FL. Histological classification should be made according to the classification criteria updated by the World Health Organization.
For more information, please visit
Although Follicular Lymphoma is generally a slow-progressing disease, it can sometimes develop into aggressive lymphoma. Follicular Lymphoma treatment is planned according to the progression and spread of the disease. The high age at diagnosis and comorbidities are other factors that may affect the treatment decision and treatment options. The FL treatment decision is based not only on disease staging but also on the patient's symptoms.
References
M. Dreyling , M. Ghielmini. et all. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology vol 32, ıssue 3, P. 298-308, March 2021 https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2820%2943163-1 [Accessed: July 2023]
https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/follicular-lymphoma#symptoms [Accessed: July 2023]
The information provided on this site is not for diagnostic or medical advice, but for informational purposes. If you have or think you have a disease to be treated, consult a specialist physician.
For adverse events related to Roche products,
To contact us about other issues;
Roche Pharma Address: Roche Müstahzarları San A.Ş. Uniq İstanbul Ayazağa Caddesi No:4D/101 34396 Maslak/İstanbul; Tel: +90 212 366 90 00 Fax: +90 212 366 95 01/03
KEP:
Roche Diagnostics Address: Roche Diagnostics Turkey A.Ş. Esentepe Mah. Kırgülü Sk. Metrocity İş Merkezi D Bl. No: 4/5 34394 Şişli /İstanbul; Tel: +90 212 306 06 06 Fax: +90 212 216 73 51
KEP:
Supervisors: Bahar Süral & Naz Kocaoğlu